Sustainability Is the New Survival Strategy
January 21, 2026
Green issues shouldn’t be treated as “woke.” Instead, they should be seen as pharma’s license to operate. Three industry experts discuss.
10 min read
False
January 21, 2026
Green issues shouldn’t be treated as “woke.” Instead, they should be seen as pharma’s license to operate. Three industry experts discuss.
10 min read
By Andrew Lewis
January 20, 2026
Decades of research have made mRNA a platform for fast, flexible therapeutic innovation, but its promise depends on partnerships.
4 min read
By Stephanie Vine
January 13, 2026
Are developers still underestimating the engineering sophistication required to scale advanced therapies in the real world? Alan Boyd discusses.
7 min read
By Mona-Elisabeth Rootwelt-Revheim
January 12, 2026
Here’s why so many people in the industry are excited about the potential of radiopharmaceuticals for diagnosis and treatment.
5 min read
By Stephen Tindal
January 9, 2026
Catalent offers clarification after recent discussions raised concerns around softgels, phthalates and potential health risks
3 min read
January 7, 2026
The life sciences sector is bracing for a year when AI delivers real returns, regulators move faster, and trial operations are finally built for modern science.
6 min read
By Stefan Lutz
January 6, 2026
Can enzyme-catalyzed processes address the limitations of traditional RNA synthesis and define the future of scalable, sustainable manufacturing of RNA therapeutics?
5 min read
By Anita Modi
December 29, 2025
Agentic AI combined with human control points creates a new paradigm for accelerating documentation while maintaining regulatory integrity.
5 min read
By Les Enterline
December 15, 2025
Clinical trials are becoming longer, costlier and more complex, but a growing number of sponsors are finding agility in a hybrid approach.
4 min read
By Martyn Williams
December 11, 2025
The UK’s pharma manufacturing base still has potential, but only if companies modernize operations, boost efficiency, and show global investors that the UK can compete on cost and capability.
6 min read
False
False
False